h
widegren
v
l
b
l
e
w
w
w
c
e
n
c
e
r
e
c
c
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
r
e
respiratori
medicin
see
front
matter
keyword
leukotrien
neutrophil
innat
defens
rhiniti
rhinoviru
summari
background
leukotrien
recruit
activ
neutrophil
accordingli
leukotrien
involv
innat
defens
action
object
examin
nasal
produc
neutrophil
activ
explor
whether
condit
neutrophil
exert
virucid
effect
vitro
vivo
method
twentythre
healthi
subject
receiv
nasal
random
shamcontrol
design
symptom
score
nasal
lavag
carri
myeloperoxidas
mpo
adefensin
monitor
indic
neutrophil
activ
eosinophil
cation
protein
ecp
macroglobulin
measur
indic
proinflammatori
cytokin
product
eosinophil
activ
plasma
exud
supernat
neutrophil
activ
vitro
assay
virucid
activ
respiratori
virus
healthi
individu
nasal
inocul
human
perform
preliminari
studi
intervent
given
random
control
design
symptom
viru
replic
antibodytitr
monitor
result
produc
statist
signific
increas
mpo
adefensin
wherea
ecp
macroglobulin
unaffect
supernat
effici
kill
human
coronaviru
respiratori
syncyti
viru
influenza
b
viru
replic
lower
subject
receiv
differ
fail
reach
statist
signific
common
cold
symptom
incid
seroconvers
unaffect
conclus
nasal
induc
select
recruitmentactiv
neutrophil
condit
neutrophil
exert
virucid
effect
vitro
may
reduc
viru
replic
vivo
suggest
condit
induc
reflect
enhanc
state
innat
defens
elsevi
ltd
right
reserv
leukotrien
metabolit
pathway
origin
find
biolog
leukotrien
compris
demonstr
biosynthesi
potent
chemotact
activ
effect
polymorphonuclear
leukocyt
accordingli
substanti
seri
subsequ
observ
regard
key
mediat
innat
immun
system
inform
role
human
airway
obtain
experi
involv
airway
challeng
leukotrien
administr
bronchial
airway
shown
increas
neutrophil
recruit
without
produc
exud
inflamm
bronchial
hyperrespons
contrast
report
effect
administ
human
nasal
airway
select
increas
human
nasal
neutrophil
activ
topic
administr
leukotrien
may
employ
enhanc
mucos
innat
immun
defens
infect
defensin
cation
antimicrobi
peptid
group
aand
bdefensin
subfamili
adefensin
major
compon
neutrophil
granul
wherea
bdefensin
found
epitheli
cell
flamand
et
al
recent
demonstr
intraven
administr
monkey
produc
increas
plasma
level
adefensin
level
could
exert
antimicrobi
effect
ex
vivo
whether
topic
administr
affect
nasal
mucos
output
adefensin
unknown
studi
examin
doseand
timedepend
effect
nasal
administr
healthi
subject
symptom
nasal
peak
inspiratori
flow
pif
select
nasal
lavag
fluid
indic
accordingli
monitor
neutrophil
granul
protein
myeloperoxidas
mpo
adefensin
indic
neutrophil
activ
analyz
order
explor
whether
neutrophil
activ
effect
involv
proinflammatori
cytokin
eosinophil
cation
protein
ecp
monitor
indic
eosinophil
activ
plasma
exud
order
explor
whether
neutrophil
activ
consequ
nasal
mucosa
term
produc
eosinophil
exud
inflamm
studi
also
studi
whether
exposur
neutrophil
vitro
induc
virucid
effect
respiratori
virus
human
coronaviru
human
respiratori
syncyti
viru
rsv
human
influenza
b
viru
final
preliminari
experi
involv
healthi
subject
examin
effect
human
induc
viru
replic
seroconvers
symptom
studi
conduct
accord
principl
express
declar
helsinki
studi
approv
institut
review
board
lund
univers
refer
number
patient
provid
written
inform
consent
collect
sampl
subsequ
analysi
subject
twentythre
subject
femal
male
age
year
recruit
inclus
criteria
neg
skinprick
test
relev
aeroallergen
exclus
criteria
allerg
rhiniti
nasal
diseas
structur
abnorm
rhinosinus
polyposi
chronic
diseas
ongo
drug
treatment
pregnanc
lactat
subject
without
medic
least
four
week
prior
studi
medic
except
studi
drug
occasion
use
overthecount
pain
reliev
allow
cours
studi
challeng
lavag
given
right
hand
side
nasal
caviti
sham
solut
isoton
salin
contain
mm
glycinesodium
hydroxid
buffer
ph
use
control
challeng
two
dose
mg
dissolv
sham
solut
given
random
order
challeng
given
singl
actuat
use
spraydevic
deliv
ml
per
actuat
washout
time
administr
least
one
week
symptom
nasal
peak
inspiratori
flow
pif
nasal
lavag
carri
challeng
well
h
thereaft
symptom
block
nose
runni
nose
irrit
score
subject
fourgrad
scale
z
symptom
z
mild
symptom
z
moder
symptom
z
sever
symptom
number
sneez
count
transform
score
z
sneez
z
sneez
z
sneez
z
sneez
four
score
block
nose
runni
nose
irrit
sneez
ad
total
nasal
symptom
score
tnss
nasal
pif
measur
use
pifmet
clementclark
harlow
uk
occas
best
three
pifrecord
use
analysi
pooldevic
use
isoton
salin
lavag
nasal
mucosa
describ
previous
volum
poolfluid
ml
dwell
time
min
highvolum
lavag
retriev
nasal
mucos
surfac
liquid
dilut
process
degre
dilut
like
similar
baselin
post
challeng
observ
lavag
carri
challeng
well
h
thereaft
analys
cayman
chemic
ann
arbour
mi
detect
limit
pgml
mpo
diagnost
develop
uppsala
sweden
detect
limit
ngml
invitrogen
burlington
ontario
canada
detect
limit
pgml
adefensin
hycult
biotechnolog
uden
netherland
detect
limit
pgml
measur
elisa
ecp
measur
use
fluoroimmunoassay
pharmacia
diagnost
uppsala
sweden
detect
limit
ngml
macroglobulin
measur
use
radioimmunoassay
detect
limit
ngml
isol
human
polymorphonuclear
leukocyt
pmn
separ
group
healthi
volunt
venou
blood
collect
tube
contain
heparin
pmn
isol
describ
previous
pmnsuspens
contain
mainli
neutrophil
eosinophil
major
contamin
cell
viabil
measur
trypan
blue
exclus
alway
greater
pmn
resuspend
cellsml
medium
without
serum
antibiot
freshli
isol
human
pmn
preincub
ml
medium
contain
mm
cytochalasin
b
min
c
ad
tube
variou
concentr
nm
incub
stop
min
transfer
tube
ice
water
bath
cell
suspens
centrifug
g
min
c
cellfre
supernat
collect
assay
virucid
activ
follow
seventyseven
healthi
subject
femal
male
age
year
enrol
screen
inclus
exclus
criteria
ident
challeng
studi
describ
addit
individu
detect
level
serum
neutral
antibodi
exclud
accordingli
subject
femal
male
age
year
random
subject
one
exclud
analysi
due
wild
type
infect
day
inocul
ie
posit
qpcr
prior
inocul
one
due
symptomat
upper
respiratori
tract
infect
unknown
caus
day
ultim
control
group
compris
ten
femal
ten
male
age
year
nine
femal
nine
male
age
year
intervent
dissolv
mm
glycinesodium
hydroxid
buffer
ph
administ
intervent
doubleblind
random
control
parallel
group
design
dose
mg
per
nasal
caviti
given
twice
daili
four
day
intervent
start
h
prior
inocul
control
solut
placebo
isoton
salin
contain
mm
glycinesodium
hydroxid
buffer
ph
nasal
spraydevic
deliv
ml
per
actuat
use
administr
order
assur
complianc
investig
perform
administr
visit
clinic
studi
day
tcid
tissu
cultur
infect
dose
ml
isoton
salin
initi
harvest
cultiv
bardin
et
al
mix
ml
isoton
salin
administ
nasal
passag
ml
per
side
use
mucos
atom
devic
wolf
tori
medic
salt
lake
citi
ut
attach
ml
syring
inocul
took
place
h
first
administr
solut
symptom
regist
morn
studi
day
lavag
procedur
administr
solut
nasal
secret
blockag
nasal
irrit
headach
sinu
ach
sore
throat
hoars
score
subject
fourgrad
scale
z
symptom
z
mild
symptom
z
moder
symptom
z
sever
symptom
seven
score
ad
divid
seven
mean
symptom
score
rang
nasal
lavag
perform
everi
morn
studi
day
symptom
registr
administr
subject
tilt
head
back
close
soft
palat
order
avoid
displac
salin
throat
ml
steril
salin
instil
nasal
caviti
use
steril
syring
three
second
head
tilt
forward
lavag
fluid
collect
steril
test
tube
via
funnel
fluid
centrifug
supernat
except
part
bound
qpcr
analysi
ml
mechan
homogen
yellow
line
di
basic
ika
staufen
germani
final
fluid
aliquot
store
c
analys
nasal
lavag
fluid
detect
qpcr
accord
messag
et
al
analysi
neutral
antibodi
serum
also
perform
describ
messag
et
al
seroconvers
defin
fourfold
increas
neutral
antibodi
titer
studi
day
observ
point
week
later
measur
nasal
lavag
fluid
surrog
marker
inflamm
associ
infect
challeng
studi
differ
symptom
level
analyt
challeng
sham
analyz
use
friedman
test
wilcoxon
sign
rank
test
vitro
studi
ttest
welch
correct
use
studi
differ
intervent
group
analyz
fisher
exact
test
serolog
data
mann
whitney
utest
pair
comparison
within
group
analyz
use
friedman
test
wilcoxon
sign
rank
test
pvalu
consid
statist
signific
power
calcul
carri
studi
exploratori
natur
sinc
similar
studi
report
provid
data
perform
calcul
nonparametr
method
comparison
challeng
studi
studi
data
normal
distribut
nasal
administr
doserang
mg
produc
nasal
symptom
followup
period
tabl
moreov
nasal
pif
unaffect
exposur
tabl
measur
nasal
lavag
fluid
order
estim
retent
nose
tabl
measur
lavag
shamchalleng
subject
median
level
ngml
vari
much
subsequ
lavag
level
increas
h
follow
challeng
mg
compar
sham
p
h
level
return
near
baselin
level
mpo
detect
nasal
lavag
fluid
sampl
ie
observ
level
mpo
increas
follow
challeng
mg
subsequ
greater
dose
mg
elev
level
fig
increas
statist
signific
dose
h
post
challeng
p
well
h
p
cf
sham
fivefold
increas
level
adefensin
mg
record
h
follow
administr
p
fig
similarli
level
increas
h
post
challeng
well
observ
point
follow
challeng
mg
effect
fail
reach
statist
signific
contrast
analyt
gradual
lower
level
record
time
follow
sham
challeng
see
increas
level
adefensin
observ
h
post
sham
challeng
cf
prior
challeng
p
p
z
baselin
drift
produc
alkalin
buffer
suggest
sensit
detect
chang
adefensin
poor
level
affect
cf
sham
tabl
ecp
macroglobulin
low
prior
challeng
increas
level
analyt
observ
point
cf
sham
tabl
rather
repeat
lavag
produc
gradual
lower
level
ecp
macroglobulin
reflect
fact
marker
undetect
observ
respect
focus
nasal
lavag
seri
conduct
follow
sham
challeng
evid
repeat
lavag
gradual
lower
analyt
level
except
adefensin
exampl
mpo
featur
reduct
observ
preand
h
post
challeng
find
emphas
necess
shamcontrol
design
experi
vitro
experi
isol
pmn
expos
vari
concentr
cellfre
supernat
collect
incub
human
coronaviru
fig
human
rsv
fig
human
influenza
b
viru
fig
result
indic
supernat
significantli
reduc
infect
virus
concentr
nm
nm
use
condit
neutrophil
nm
focus
control
group
whole
signific
viru
replic
observ
three
five
day
follow
inocul
fig
furthermor
group
present
mild
yet
statist
signific
nasal
symptom
common
cold
fig
twelv
control
subject
seroconvert
six
subject
convinc
evid
viru
replic
ie
copiesml
lavag
three
consecut
day
respons
peak
three
day
inocul
group
also
featur
greater
level
nasal
lavag
fluid
day
four
follow
inocul
compar
remaind
group
median
level
pgml
pgml
respect
p
eight
control
subject
neg
viru
test
day
one
control
subject
posit
viru
seroconvert
convers
one
subject
neg
viru
seroconvert
intervent
associ
lower
viral
shed
compar
control
entir
postinocul
period
chang
fail
reach
statist
signific
fig
howev
top
five
virusshed
individu
four
found
control
group
reduc
clearli
posit
infect
defin
substanti
viru
replic
copiesml
lavag
fluid
three
consecut
day
combin
seroconvers
reduc
highgrad
viral
shed
copiesml
lavag
symptom
score
differ
group
fig
seroconvers
occur
eleven
subject
receiv
nasal
lavag
fluid
level
differ
group
data
shown
studi
demonstr
nasal
administr
select
increas
local
neutrophil
activ
reflect
increas
level
mpo
adefensin
nasal
mucos
surfac
liquid
furthermor
show
condit
neutrophil
produc
factor
exert
virucid
effect
toward
key
respiratori
virus
human
coronaviru
rsv
influenza
b
viru
final
preliminari
experi
involv
healthi
human
studi
explor
whether
nasal
administr
affect
outcom
lowdos
inocul
observ
interest
regard
amplifi
innat
immun
respons
nasal
administr
increas
lavag
fluid
level
mpo
studi
indic
increas
neutrophil
activ
statist
signific
respons
detect
alreadi
first
employ
dose
ie
mg
second
dose
produc
respons
similar
magnitud
despit
fact
ten
time
greater
suggest
flat
respons
curv
particular
doserang
effect
numer
greater
h
post
challeng
h
indic
rapid
transient
respons
find
rapidli
clear
nasal
mucosa
retriev
lavag
within
h
nasal
administr
might
account
effect
profil
agreement
present
find
martin
et
al
studi
involv
healthi
subject
show
bronchial
instil
ml
solut
mg
increas
neutrophil
number
balfluid
taken
togeth
observ
indic
recruit
activ
neutrophil
human
airway
includ
nasal
airway
heighten
neutrophil
activ
also
suggest
present
observ
nasal
lavag
fluid
level
adefensin
level
increas
median
h
follow
challeng
mg
adefensin
consist
increas
also
observ
point
cf
sham
chang
fail
reach
statist
signific
wide
distribut
data
adefensin
fact
alkalin
buffer
sham
appear
increas
baselin
might
contribut
failur
detect
specif
effect
convincingli
howev
observ
flamand
et
al
indic
increas
plasma
level
adefensin
monkey
human
follow
intraven
administr
furthermor
present
studi
neutrophil
activ
vitro
releas
factor
virucid
activ
human
coronaviru
rsv
influenza
b
viru
result
extend
previou
observ
demonstr
releas
antimicrobi
compound
includ
adefensin
follow
stimul
neutrophil
taken
togeth
present
observ
suggest
adefensin
part
innat
defens
system
upper
respiratori
tract
featur
enhanc
nasal
administr
proinflammatori
cytokin
attract
neutrophil
eg
intranas
administr
recombin
human
increas
neutrophil
number
nasal
smear
studi
nasal
lavag
fluid
level
unaffect
topic
administr
accordingli
record
increas
neutrophil
activ
ie
elev
level
mpo
might
involv
mechan
contrast
condit
character
increas
neutrophil
activ
eg
viral
infect
thought
central
mediat
neutrophil
respons
convers
present
observ
keep
notion
neutrophil
activ
mediat
may
diseaselik
mechan
rather
featur
innat
immun
defens
system
vitro
observ
suggest
possibl
act
chemoattract
eosinophil
activ
eosinophil
also
eosinophil
enter
human
bronchial
airway
follow
allergen
challeng
chemotact
desensit
suggest
tabl
wherea
sham
challeng
increas
level
adefensin
data
express
median
ae
iqr
n
z
denot
p
p
pair
comparison
exposur
vivo
togeth
observ
suggest
associ
eosinophil
activ
contrast
present
studi
increas
gener
mpo
lavag
fluid
level
ecp
unaffect
indic
nasal
granulocyt
activ
mediat
human
nasal
airway
involv
eosinophil
exclud
possibl
may
increas
eosinophil
activ
elev
number
eosinophil
would
present
time
challeng
eg
ongo
allerg
rhiniti
asthma
administ
bronchial
airway
patient
mild
asthma
without
focu
airway
eosinophil
activ
howev
far
avail
human
vivo
observ
argu
role
proeosinophil
factor
exampl
receptor
antagonist
effect
allergeninduc
eosinophilia
asthma
plasma
exud
key
featur
airway
inflamm
process
compris
extravas
lumin
entri
bulk
plasma
includ
high
molecular
weight
protein
kda
monitor
analysi
plasma
protein
mucos
surfac
liquid
accordingli
airway
diseas
character
inflamm
level
plasma
protein
nasal
lavageand
balfluid
may
reflect
degre
ongo
inflamm
lavag
fluid
level
macroglobulin
unaffect
follow
challeng
indic
leukotrien
exert
plasma
exud
produc
effect
human
nasal
airway
dose
use
contrast
bend
et
al
studi
anesthet
rabbit
report
increas
vascular
permeabl
follow
nasal
challeng
specif
explan
discrep
find
speci
differ
may
one
reason
present
observ
agreement
observ
man
martin
et
al
figur
condit
neutrophil
exert
antivir
effect
supernat
neutrophil
condit
produc
virucid
effect
human
coronaviru
rsv
b
influenza
b
viru
c
control
experi
indic
effect
specif
interact
neutrophil
data
express
mean
tcid
sd
one
experi
repres
least
two
independ
experi
denot
p
figur
control
subject
present
viral
replic
common
cold
symptom
data
control
subject
inocul
subject
present
replic
peak
three
day
follow
inocul
indic
qpcr
mild
nasal
symptom
common
cold
b
data
express
mean
ae
sem
n
z
denot
p
denot
p
pair
comparison
baselin
level
prior
inocul
unaffect
level
albumin
well
total
protein
balfluid
observ
healthi
subject
follow
segment
challeng
avail
observ
man
thu
suggest
dose
produc
increas
neutrophil
activ
produc
exud
inflamm
bachert
et
al
report
interest
tempor
relationship
increas
level
mpo
nasal
secret
fall
viru
replic
natur
acquir
infect
find
suggest
heighten
neutrophil
activ
benefici
context
viral
exposur
upper
respiratori
tract
indirectli
support
present
vitro
observ
neutrophil
produc
factor
activ
respiratori
virus
moreov
previou
studi
implic
neutrophil
import
player
respons
infect
gaudreault
et
al
demonstr
iv
upregul
antimicrobi
peptid
reduc
viral
load
influenza
infect
mice
vivo
line
employ
inocul
explor
effect
repeat
nasal
administr
rhinoviru
infect
preliminari
studi
dose
investig
mg
chosen
base
present
doserespons
experi
involv
wherebi
increas
neutrophil
activ
induc
without
produc
exud
inflamm
symptom
elect
use
lowdos
tcid
viru
challeng
shown
effect
induc
cold
copdsubject
furthermor
believ
better
model
natur
transmiss
viru
infect
inocul
occur
small
amount
viru
follow
replic
high
titr
result
symptom
induct
would
case
highdos
challeng
model
inocul
dose
high
tcid
perform
studi
signific
viru
replic
observ
three
five
day
follow
inocul
control
group
whole
furthermor
group
present
mild
yet
statist
signific
nasal
symptom
common
cold
minor
increas
nasal
mucos
output
howev
unlik
highdos
challeng
subject
becom
infect
control
subject
seroconvert
evid
viru
replic
high
viru
titr
lower
expect
number
infect
subject
like
hamper
abil
detect
statist
signific
effect
viral
outcom
nonetheless
sever
present
observ
suggest
might
affect
viru
replic
exampl
degre
viral
shed
reduc
nearli
compar
control
group
also
top
five
virusshed
individu
four
found
control
group
howev
like
part
reflect
inferior
power
parallel
group
design
well
issu
number
infect
subject
chang
fail
reach
statist
signific
data
togeth
observ
vitro
promis
symptom
incid
seroconvers
affect
accordingli
provid
convinc
evid
prevent
treatment
common
cold
infect
caus
studi
greater
number
infect
subject
properli
power
use
data
present
studi
warrant
explor
whether
nasal
administr
use
prevent
treat
upper
respiratori
tract
infect
also
would
interest
explor
effect
bacteri
infect
neutrophil
phagocytosi
key
import
clear
infect
conclud
nasal
administr
present
doserang
produc
increas
nasal
neutrophil
activ
potenti
reflect
enhanc
state
innat
immun
defens
without
associ
appar
untoward
effect
furthermor
potenti
exert
antimicrobi
effect
respiratori
tract
infect
howev
studi
intervent
undertaken
effect
respiratori
infect
studi
vivo
warrant
confirm
hypothesi
pierr
borgeat
loui
flamand
lennart
greiff
sebastian
johnston
reciev
temporari
grant
sweden
ab
partli
financ
studi
sweden
ab
took
figur
comparison
viral
replic
common
cold
symptom
two
group
viru
replic
nasal
symptom
b
control
group
viru
replic
lower
differ
cf
control
group
fail
reach
statist
signific
overal
well
timepoint
nasal
symptom
common
cold
mild
unaffect
data
express
mean
ae
sem
n
z
control
part
decid
studi
design
role
data
collect
analysi
decis
publish
prepar
manuscript
otherwis
author
report
compet
interest
